Communiqués Outlook Therapeutics, Inc.

Actions

OTLK

US69012T3059

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
0,6400 ^USD	+5,09 %		-4,79 %	-59,49 %

17/08	Le traitement d'EyePoint contre la DMLA échoue en phase finale, l'action s'effondre	RE
17/08	Outlook Therapeutics : un initié achète pour 2 499 999 $ d'actions, selon un récent dépôt auprès de la SEC	MT

Communiqués

14/08	Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™	AQ
13/08	Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants	AQ
12/08	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants	AQ
06/08	Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026	AQ
05/08	Outlook Therapeutics Secures FDA Approval For LYTENAVA™	AQ
24/07	Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD	AQ
17/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD	AQ
16/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD	AQ
01/06	Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
28/05	Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
26/05	Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
15/05	Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update	AQ
23/04	Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering	AQ
22/04	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
21/04	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
07/04	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA	AQ
25/03	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering	AQ
24/03	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering	AQ
23/03	Outlook Therapeutics Announces Proposed Public Offering	AQ
16/03	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note	AQ
05/03	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
19/02	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland	AQ
17/02	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update	AQ
11/02	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter	AQ
06/01	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development	AQ